Skip to main content
Top
Published in: Supportive Care in Cancer 9/2018

01-09-2018 | Original Article

A cohort study on protocol-based nurse-led out-patient management of post-chemotherapy low-risk febrile neutropenia

Authors: Fiona Lim Mei Ying, Maria Choy Yin Ping, Macy Tong, Elaine Yim Pik Yan, Tracy Lui Siu Yee, Lam Yuk Ting, Anita Lo Wing Sim, Lui Cheuk Yu, Bosco Lam Hoi Shiu, Ashley Cheng Chi Kin

Published in: Supportive Care in Cancer | Issue 9/2018

Login to get access

Abstract

Purpose

International guidelines adopt risk stratification approach to manage patients with low-risk febrile neutropenia patients. We developed this out-patient program using shared-care model with professional input and patient empowerment, so as to reduce patients’ psychological burden from hospitalization and to improve the cost-effectiveness of management.

Method

This is a prospective cohort study to compare the efficacy and safeness of the out-patient program when compared with traditional in-patient care. Patients with solid tumors, developed febrile neutropenia with Multinational Association of Supportive Care in Cancer score of at least 21, and good performance status were included. After initial assessment and the first dose of oral antibiotics, patients were observed in the ambulatory center. Stable patients were discharged home after 4 h of observation and nurse counseling. Patients’ condition and clinical progress were regularly reviewed by specialist nurses within the following week by telephone and nurse clinic follow-up. The primary objective of the study is success rate, which defined as the resolution of fever and infection, without hospitalization or any change in antibiotics.

Results

From September 2014 to December 2016, a total of 38 patients were enrolled. Majority were female with breast cancer (97%). Two patients required hospitalization due to persistent fever. The success rate of the out-patient program was not significantly different from the historical in-patient cohort (94.9 versus 97.4%, p = 0.053). No mortality was observed. Patients’ compliance to the program was 100%, to telephone follow-up, nurse clinic visits, and daily temperature record.

Conclusion

Out-patient management of patients with low-risk febrile neutropenia is effective and safe through implementation of a structured protocol with joint inputs and engagement from clinicians, oncology nurses, and patients.
Literature
1.
go back to reference Gaieski DF, Mikkelsen ME, Band RA, Pines JM, Massone R, Furia F, Massone R, Furia FF, Shofer FS, Goyal M (2010) Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 38(4):1045–1053CrossRefPubMed Gaieski DF, Mikkelsen ME, Band RA, Pines JM, Massone R, Furia F, Massone R, Furia FF, Shofer FS, Goyal M (2010) Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 38(4):1045–1053CrossRefPubMed
2.
go back to reference Klastersky J, Paesmans M, Ruberstein EB et al (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038–3051CrossRefPubMed Klastersky J, Paesmans M, Ruberstein EB et al (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038–3051CrossRefPubMed
3.
go back to reference Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia : a prospective study to validate the multinational association for supportive care of cancer (MASCC) risk index score. Support Care Cancer 12:555–560CrossRefPubMed Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia : a prospective study to validate the multinational association for supportive care of cancer (MASCC) risk index score. Support Care Cancer 12:555–560CrossRefPubMed
4.
go back to reference Vidal L, Paul M, Ben-Dor LI et al (2004) Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients : a systemic review and meta-analysis of randomized trials. J Antimicrob Chemother 54:29–37CrossRefPubMed Vidal L, Paul M, Ben-Dor LI et al (2004) Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients : a systemic review and meta-analysis of randomized trials. J Antimicrob Chemother 54:29–37CrossRefPubMed
6.
go back to reference Carstensen M, Sorensen JB (2008) Outpatient management of febrile neutropenia: time to revise the present treatment strategy. J Support Oncol 6:199–208PubMed Carstensen M, Sorensen JB (2008) Outpatient management of febrile neutropenia: time to revise the present treatment strategy. J Support Oncol 6:199–208PubMed
7.
go back to reference Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by infectious diseases society of America. Clin Infect Dis 54:e56–e93CrossRef Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by infectious diseases society of America. Clin Infect Dis 54:e56–e93CrossRef
9.
go back to reference Klastersky J, de NJ, Rolston K et al (2016) Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol 27(suppl 5):v111–v118CrossRefPubMed Klastersky J, de NJ, Rolston K et al (2016) Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol 27(suppl 5):v111–v118CrossRefPubMed
10.
go back to reference Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340CrossRefPubMed Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340CrossRefPubMed
11.
go back to reference Curtin JA, Marshall BD Jr (1962) Use of antibiotics in cancer and leukemia. J Chronic Dis 15:713–718CrossRefPubMed Curtin JA, Marshall BD Jr (1962) Use of antibiotics in cancer and leukemia. J Chronic Dis 15:713–718CrossRefPubMed
12.
go back to reference Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R (1994) Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 12:107–114CrossRefPubMed Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R (1994) Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 12:107–114CrossRefPubMed
13.
go back to reference Klastersky J, Paesmans M, Aoun M, Georgala A, Loizidou A, Lalami Y, Dal Lago L (2016) Clinical research in febrile neutropenia in cancer patients: past achievements and perspectives for the future. World J Clin Infect Dis 6(3):37–60CrossRef Klastersky J, Paesmans M, Aoun M, Georgala A, Loizidou A, Lalami Y, Dal Lago L (2016) Clinical research in febrile neutropenia in cancer patients: past achievements and perspectives for the future. World J Clin Infect Dis 6(3):37–60CrossRef
14.
go back to reference Hui P, Leung KS, Poon CW et al (2011) Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the multinational association for supportive care in cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network. Support Care Cancer 19:1625–1635CrossRefPubMed Hui P, Leung KS, Poon CW et al (2011) Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the multinational association for supportive care in cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network. Support Care Cancer 19:1625–1635CrossRefPubMed
15.
go back to reference Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, Kuderer NM, Langston AA, Marr KA, Rolston KVI, Ramsey SD (2013) Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 31(6):794–810CrossRefPubMed Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, Kuderer NM, Langston AA, Marr KA, Rolston KVI, Ramsey SD (2013) Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 31(6):794–810CrossRefPubMed
16.
go back to reference Klastersky J, Paesmans M, Georgala A, Muanza F, Plehiers B, Dubreucq L, Lalami Y, Aoun M, Barette M (2006) Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 24:4129–4134CrossRefPubMed Klastersky J, Paesmans M, Georgala A, Muanza F, Plehiers B, Dubreucq L, Lalami Y, Aoun M, Barette M (2006) Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 24:4129–4134CrossRefPubMed
17.
go back to reference Cherif H, Johansson E, Bjorkholm M et al (2006) The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica 91(2):215–222PubMed Cherif H, Johansson E, Bjorkholm M et al (2006) The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica 91(2):215–222PubMed
18.
go back to reference Girmenia C, Russo E, Carmosino I, Breccia M, Dragoni F, Latagliata R, Mecarocci S, Morano SG, Stefanizzi C, Alimena G (2007) Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia. Ann Hematol 86:263–270CrossRefPubMed Girmenia C, Russo E, Carmosino I, Breccia M, Dragoni F, Latagliata R, Mecarocci S, Morano SG, Stefanizzi C, Alimena G (2007) Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia. Ann Hematol 86:263–270CrossRefPubMed
19.
go back to reference Innes HE, Lim SL, Hall A, Chan SY, Bhalla N, Marshall E (2008) Management of febrile neutropenia in solid tumors and lymphomas using multinational association for supportive care in cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer 16:485–494CrossRefPubMed Innes HE, Lim SL, Hall A, Chan SY, Bhalla N, Marshall E (2008) Management of febrile neutropenia in solid tumors and lymphomas using multinational association for supportive care in cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer 16:485–494CrossRefPubMed
20.
go back to reference Sebban C, Dussart S, Fuhrmann C, Ghesquieres H, Rodrigues I, Geoffrois L, Devaux Y, Lancry L, Chvetzoff G, Bachelot T, Chelghoum M, Biron P (2008) Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge. Support Care Cancer 16:1017–1023CrossRefPubMed Sebban C, Dussart S, Fuhrmann C, Ghesquieres H, Rodrigues I, Geoffrois L, Devaux Y, Lancry L, Chvetzoff G, Bachelot T, Chelghoum M, Biron P (2008) Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge. Support Care Cancer 16:1017–1023CrossRefPubMed
21.
go back to reference Teuffel O, Ethier MC, Alibhai SMH, Beyene J, Sung L (2011) Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis. Ann Oncol 22:2358–2365CrossRefPubMed Teuffel O, Ethier MC, Alibhai SMH, Beyene J, Sung L (2011) Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis. Ann Oncol 22:2358–2365CrossRefPubMed
22.
go back to reference Klastersky J, Ameye L, Maertens et al (2007) Bacteraemia in febrile neutropenic cancer patients. Int J Antimircob Agents 30(suppl 1):S51–S59CrossRef Klastersky J, Ameye L, Maertens et al (2007) Bacteraemia in febrile neutropenic cancer patients. Int J Antimircob Agents 30(suppl 1):S51–S59CrossRef
23.
go back to reference Nirenberg A, Reame NK, Cato KD, Larson EL (2010) Oncology nurses’ use of National Comprehensive Cancer Network clinical practice guidelines for chemotherapy-induced and febrile neutropenia. Oncol Nurs Forum 37:765–773CrossRefPubMed Nirenberg A, Reame NK, Cato KD, Larson EL (2010) Oncology nurses’ use of National Comprehensive Cancer Network clinical practice guidelines for chemotherapy-induced and febrile neutropenia. Oncol Nurs Forum 37:765–773CrossRefPubMed
24.
go back to reference Innes HE, Smith DB, O’Reilly SM et al (2003) Oral antibiotics with early hospital discharge compared with in-patients intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomized controlled single center study. Br J Cancer 89:43–49CrossRefPubMedPubMedCentral Innes HE, Smith DB, O’Reilly SM et al (2003) Oral antibiotics with early hospital discharge compared with in-patients intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomized controlled single center study. Br J Cancer 89:43–49CrossRefPubMedPubMedCentral
25.
go back to reference Teuffel E, Amir, Alibhai S et al (2011) Cost-effectiveness of outpatient treatment for febrile neutropenia in adult cancer patients. B J Cancer 104:1377–1383CrossRef Teuffel E, Amir, Alibhai S et al (2011) Cost-effectiveness of outpatient treatment for febrile neutropenia in adult cancer patients. B J Cancer 104:1377–1383CrossRef
26.
go back to reference Elting LS, Lu C, Escalante CP, Giordano SH, Trent JC, Cooksley C, Avritscher EBC, Shih YCT, Ensor J, Bekele BN, Gralla RJ, Talcott JA, Rolston K (2008) Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. JCO 26(4):606–611CrossRef Elting LS, Lu C, Escalante CP, Giordano SH, Trent JC, Cooksley C, Avritscher EBC, Shih YCT, Ensor J, Bekele BN, Gralla RJ, Talcott JA, Rolston K (2008) Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. JCO 26(4):606–611CrossRef
Metadata
Title
A cohort study on protocol-based nurse-led out-patient management of post-chemotherapy low-risk febrile neutropenia
Authors
Fiona Lim Mei Ying
Maria Choy Yin Ping
Macy Tong
Elaine Yim Pik Yan
Tracy Lui Siu Yee
Lam Yuk Ting
Anita Lo Wing Sim
Lui Cheuk Yu
Bosco Lam Hoi Shiu
Ashley Cheng Chi Kin
Publication date
01-09-2018
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 9/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-018-4157-6

Other articles of this Issue 9/2018

Supportive Care in Cancer 9/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine